Placeholder Banner

BIO Comments on ICER’s Value Assessment Framework for Transformative Therapies

September 6, 2019

We are writing on behalf of the Biotechnology Innovation Organization (BIO) to provide comments on the Institute for Clinical and Economic Review’s (ICER’s) solicitation for input on draft revisions to its Value Assessment Framework for the assessment of “single or short-term transformative therapies” (SSTs).

...

We appreciate ICER’s recognition that the burgeoning field of transformative and curative therapies requires serious discussion around how these treatments are valued by not just payors, but society at large. These therapies have the potential to fundamentally change how we view the treatment of disease. Yet as we strive to shift our health care system to one that rewards valuable care, BIO is concerned that the science of value assessment for all therapies – not just those that are curative or transformational – is woefully behind where it should be for these tools to be used in a substantive way.

Download Full Comments Below
BIO Comments on SST Updates
Discover More
We are writing to express our strong support for the bipartisan Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act). The legislation, which was introduced by Reps. John Joyce (R-PA) and Wiley Nickel (D-NC) in September,1 corrects a…
The meeting of global trade ministers at the World Trade Organization’s 13th Ministerial Conference in Abu Dhabi offers an important opportunity to build on and strengthen the open and rules-based international trading system to support better…
The companies and workers represented by the undersigned organizations stepped up to combat the COVID-19 pandemic, investing in and creating hundreds of partnerships at an unprecedented speed and scale to leverage U.S. innovation and manufacturing…